

B

	Days post intracranial cell implantation									
	9					27				
non-targeted	1,3870	3,6140	1,6020	0,670500	1,2410	21,3300	6,3510	4,7630	20,250000	22,4800
RGD4C/AAVP Grp78-HSVtk	6,8780	3,6040	2,8230	0,729400	1,8610	6,7690	8,6780	6,6900	28,780000	28,7800
TMZ	0,4734	0,2085	0,8918	0,408500	0,7929	7,3300	1,9860	1,1360	3,884000	5,5140
RGD4C/AAVP Grp78-HSVtk +TMZ	3,2800	6,3510	4,3330	0,652000	0,5072	0,7777	2,2350	0,7837	1,859000	2,1840

C

	Days post intracranial cell implantation									
	9					27				
non-targeted	100,	100,	100,	100,	100,	1252,569	372,952	279,6993	1189,148	1320,101
RGD4C/AAVP Grp78-HSVtk	100,	100,	100,	100,	100,	212,9232	272,972	210,4382	905,2933	905,2933
TMZ	100,	100,	100,	100,	100,	1320,673	357,825	204,6773	699,7946	993,4777
RGD4C/AAVP Grp78-HSVtk +TMZ	100,	100,	100,	100,	100,	25,71215	73,89309	25,91052	61,46186	72,20694

Figure 4- Therapeutic response of orthotopic U87 glioblastoma to combination of TMZ with RGD4C/AAVP-Grp78-HSVtk plus GCV